EUCTR2005-001638-34-GB进行中（未招募）1 期
A phase IV, single group study to evaluate the magnitude of antibody response, its persistence and avidity maturation following meningococcal serogroup C conjugate booster vaccination in older children up to ten years after receipt of three doses in infancy and a booster in the second year of life - Nava booster
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •No contraindications to vaccination as specified in the Green Book” – Immunisation Against Infectious Disease, HMSO.
- •Written informed consent obtained from the child and their parent or legal guardian
- •Child originally enrolled in the primary immunisation study and completed the booster phase in the second year of life
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Current (to be checked prior to each vaccination):
- •Generalised acute systemic illness on the day of immunisation
- •Oral temperature >38oC on the day of immunisation
研究者
相似试验
进行中（未招募）
1 期
A Phase IV, single group study to evaluate the immunogenicity and safety in UK laboratory workers of a licensed Hib and meningococcal C conjugate combined vaccine (Menitorix) - StaMeInvestigating the immunogenicity and safety of a licensed Hib and meninigococcal C combined conjugate vaccine (Menitorix) in laboratory workers.MedDRA version: 14.0 Level: LLT Classification code 10027276 Term: Meningococcal meningitis System Organ Class: 10021881 - Infections and infestationsEUCTR2006-004302-74-GBHealth Protection Agency
进行中（未招募）
1 期
A Phase IV, single group study to evaluate the immune response to licensed seasonal influenza vaccine and relationship of this to cytomegalovirus-associated immunosenescence in UK older adults aged 50-80 years.EUCTR2006-006563-23-GBHealth Protection Agency
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-PLBoehringer Ingelheim RCV GmbH & Co KG282
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 17.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-ROBoehringer Ingelheim RCV GmbH & Co KG70
招募中
4 期
Multicentric study to assess the safety of qHPV vaccineCTRI/2024/05/067838Serum Institute of India Pvt Ltd